Anteris Technologies Ltd (ASX: AVR) presented new data from the DurAVR First-In-Human Study at the TVT Conference, revealing sustained haemodynamic performance of the DurAVR THV (transcatheter heart valve) at the one-year and 30-day follow-up points. The results showed that the DurAVR THV was successfully implanted in all cases without any device-related complications. The first 12 patients who completed the one-year follow-up demonstrated sustained haemodynamic performance, with a mean effective orifice area (EOA) of 1.98 cm2 and mean pressure gradients (MPG) of 9.22 mmHg.
All 20 study patients reached their 30-day follow-up, and the results remained consistent with previous data, showing a significant increase in EOAs and a decrease in MPG. Anteris Technologies' CEO and CMO expressed satisfaction with the results, highlighting the unique clinical characteristics of DurAVR THV and its potential as an important treatment option for aortic stenosis patients. Anteris Technologies aims to provide superior and durable solutions for structural heart conditions through innovative technologies.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
